GlassScriptPhysician profile
Peter G Spitzer
NPI 1801820188
$3,023.94
in general payments reported to CMS, 2019-2025
27 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $596 · 2022: $19.40 · 2023: $35.67 · 2024: $243 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $473.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $431.52 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Viiv Healthcare Company | $376.27 | 2019-2025 | Dovato |
| Janssen Biotech, INC. | $287.71 | 2019-2020 | |
| Insmed, INC. | $261.84 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $152.36 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $137.97 | 2019-2025 | Rezzayo, Vabomere, Orbactiv |
| Abbvie INC. | $100.32 | 2024-2025 | |
| Janssen Products, LP | $99.99 | 2019 | |
| Amgen INC. | $97.54 | 2019 | |
| Aimmune Therapeutics, INC. | $85.53 | 2023-2025 | Vowst |
| Tetraphase Pharmaceuticals, INC. | $84.88 | 2019 | |
| La Jolla Pharmaceutical Company | $77.29 | 2024-2025 | Xacduro, Zevtera |
| Allergan, INC. | $52.36 | 2019 | |
| Astellas Pharma US INC | $43.18 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.74 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $38.00 | 2019 | |
| Vyera Pharmaceuticals, LLC | $32.51 | 2019-2020 | |
| Pfizer INC. | $24.51 | 2025 | |
| Urgo Medical North America, LLC | $23.53 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Shire North American Group INC | $19.58 | 2019 | |
| Mylan Institutional INC. | $16.34 | 2019 | |
| Exact Sciences Corporation | $16.05 | 2025 | Cologuard Collection Kit |
| Theratechnologies INC. | $13.77 | 2019 | |
| Nabriva Therapeutics, Plc | $13.71 | 2020 | |
| Napo Pharmaceuticals INC | $12.41 | 2019 | |
| Redhill Biopharma INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Spitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.